POLYMORPHIC OXIDATION OF DEBRISOQUINE IN LUNG-CANCER PATIENTS

被引：32

作者：

BENITEZ, J

LADERO, JM

JARA, C

CARRILLO, JA

COBALEDA, J

LLERENA, A

VARGAS, E

MUNOZ, JJ

机构：

[1] UNIV EXTREMADURA,DEPT PHARMACOL & PSYCHIAT,BADAJOZ,SPAIN

[2] UNIV COMPLUTENSE MADRID,DEPT MED,MADRID 3,SPAIN

来源：

EUROPEAN JOURNAL OF CANCER | 1991年 / 27卷 / 02期

关键词：

D O I：

10.1016/0277-5379(91)90477-U

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Oxidative polymorphism of debrisoquine (DBQ) was assessed in 84 patients (81 male) with histologically proven bronchogenic carcinoma and in 143 healthy male smokers. 80 (95%) patients and 133 (93%) controls, with a metabolic ratio (MR) below 12.6, were classified as extensive metabolisers of DBQ (no significant difference between patients and controls). Only 1 of the 73 patients with epidermoid or microcytic carcinomas was classified as a poor metaboliser (PM) (P = 0.031 compared with controls). 63 patients (75%) and 110 controls (77%) showed a very fast oxidative rate, with MR values under 1 (not significant). The EM phenotype of DBQ might be a secondary genetic risk factor for developing bronchogenic carcinoma in male smokers.

引用

收藏

页码：158 / 161

页数：4

相关论文

共 23 条

[1] METABOLIC OXIDATION PHENOTYPES AS MARKERS FOR SUSCEPTIBILITY TO LUNG-CANCER [J].

AYESH, R ;

IDLE, JR ;

RITCHIE, JC ;

CROTHERS, MJ ;

HETZEL, MR .

NATURE, 1984, 312 (5990) :169-170

[2]

CAPORASO N, 1989, CANCER RES, V49, P3675

[3] THE DISTRIBUTION OF DEBRISOQUINE METABOLIC PHENOTYPES AND IMPLICATIONS FOR THE SUGGESTED ASSOCIATION WITH LUNG-CANCER RISK [J].

CAPORASO, N ;

PICKLE, LW ;

BALE, S ;

AYESH, R ;

HETZEL, M ;

IDLE, J .

GENETIC EPIDEMIOLOGY, 1989, 6 (04) :517-524

[4] LUNG-CANCER AND THE DEBRISOQUINE METABOLIC PHENOTYPE [J].

CAPORASO, NE ;

TUCKER, MA ;

HOOVER, RN ;

HAYES, RB ;

PICKLE, LW ;

ISSAQ, HJ ;

MUSCHIK, GM ;

GREENGALLO, L ;

BUIVYS, D ;

AISNER, S ;

RESAU, JH ;

TRUMP, BF ;

TOLLERUD, D ;

WESTON, A ;

HARRIS, CC .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (15) :1264-1272

[5]

EVANS DAP, 1977, LANCET, V2, P584

[6] XENOBIOTIC AND ENDOBIOTIC INHIBITORS OF CYTOCHROME-P-450DBL FUNCTION, THE TARGET OF THE DEBRISOQUINE SPARTEINE TYPE POLYMORPHISM [J].

FONNEPFISTER, R ;

MEYER, UA .

BIOCHEMICAL PHARMACOLOGY, 1988, 37 (20) :3829-3835

[7] CARCINOGENS, DRUGS, AND CYTOCHROMES-P-450 [J].

GELBOIN, HV .

NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (02) :105-107

[8] CHARACTERIZATION OF THE COMMON GENETIC-DEFECT IN HUMANS DEFICIENT IN DEBRISOQUINE METABOLISM [J].

GONZALEZ, FJ ;

SKODA, RC ;

KIMURA, S ;

UMENO, M ;

ZANGER, UM ;

NEBERT, DW ;

GELBOIN, HV ;

HARDWICK, JP ;

MEYER, UA .

NATURE, 1988, 331 (6155) :442-446

[9]

GUENGERICH FP, 1988, CANCER RES, V48, P2946

[10] ASSESSMENT OF THE DEBRISOQUIN AND DEXTROMETHORPHAN PHENOTYPING TESTS BY GAUSSIAN MIXTURE DISTRIBUTIONS ANALYSIS [J].

HENTHORN, TK ;

BENITEZ, J ;

AVRAM, MJ ;

MARTINEZ, C ;

LLERENA, A ;

COBALEDA, J ;

KREJCIE, TC ;

GIBBONS, RD .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (03) :328-333